Form 4: Molina Healthcare Director Daniel Cooperman Reports Acquisition of Common Stock

Director Daniel Cooperman reports acquiring 136 shares of Molina Healthcare common stock on April 1, 2024, as part of the company's equity incentive plan.

Summary

• On April 1, 2024, Daniel Cooperman, a director of Molina Healthcare, Inc., acquired 136 shares of common stock.
• The acquisition was part of the Issuer's 2019 Equity Incentive Plan, related to Cooperman's service as a director.
• The shares were granted at a price of $404.20 per share, reflecting the closing price of Molina Healthcare's common stock on that day.
• This acquisition increases Cooperman's direct ownership to 5,789 shares.
• The annual equity award to each director was set at $220,000, with one quarter, or $55,000, to be granted on the first day of each quarter.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating a stable and well-governed company. The sentiment is neutral to slightly positive.

Positives

• The equity incentive plan aligns director compensation with company performance.
• Director Cooperman increased his stake in the company.

Future Outlook

NA

Industry Context

This filing is a routine disclosure related to director compensation and stock ownership, common in publicly traded companies. It reflects standard practices for aligning director interests with shareholder value.

Comparison to Industry Standards

• Director compensation packages, including equity grants, are common practice among publicly traded healthcare companies.
• Companies like UnitedHealth Group, Anthem (now Elevance Health), and Cigna also utilize equity-based compensation for their directors.
• The specific value and structure of these grants vary based on company size, performance, and compensation philosophy.
• The $220,000 annual equity award appears to be within a reasonable range for directors of companies with a similar market capitalization to Molina Healthcare.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director interests with company performance.
• The transaction has no material impact on employees, customers, suppliers, or creditors.

Key Dates